Saturday 24 Oct, 2020 11:03 AM
Site map | Locate Us | Login
   L&T to consider special dividend     S&P, Nasdaq close higher     Tata Motors bags order for 6,413 mini trucks from Andhra govt    Nestle India Q2 PAT declines 1.4% YoY    Yes Bank posts Q2 PAT at Rs 129 cr; NII falls 9.7% YoY    Tech Mahindra Q2 PAT declines 5% YoY to Rs 1065 cr    JSW Steel Q2 PAT slides 38% YoY     Chennai Petroleum Corporation Ltd leads losers in 'A' group    Vishal Fabrics Ltd leads losers in 'B' group    Surya Roshni spurts on winning orders    Volumes spurt at Aditya Birla Fashion & Retail Ltd counter    Airtel Africa Q2 net profit declines 8.8%    Real Estate stocks edge lower    IDBI Bank rises after decent Q2 performance    Coal India Ltd in demand 
Saravan Stocks
       
Hot Pursuit
Scrips, which has significant changes during the market hours.
Lupin, Cipla spurt after Perrigo recalls albuterol sulfate inhalation aerosols
18-Sep-20   11:24 Hrs IST

Lupin jumped 6.75% to Rs 1108. The stock rose as much as 7.39% at the day's high at Rs 1114.65 today, which is also 52-week high for the counter.

Cipla surged 5.84% to Rs 796. The scrip jumped as much as 6.35% at the day's high at Rs 799.80 today.

Perrigo Company, the Dublin-based maker of over-the-counter and generic health products, already halted production and distribution of the aerosols. These actions are being taken out of an abundance of caution as a result of complaints that some units may not dispense due to clogging. Perrigo's generic albuterol sulfate inhalation aerosol was developed in partnership with and manufactured by Catalent Pharma Solutions.

Corrective action plans are underway and a definitive timeline for product reintroduction has not been determined at this time, Perrigo said in a statement.

A foreign brokerage firm reportedly said the setback for Perrigo has come as an unexpected positive for Lupin and Cipla. Lupin and Cipla are Perrigo's competitors in the $850-900 million US albuterol sulfate market.

Cipla received approval from the United States Food and Drug Administration (USFDA) for its albuterol sulphate inhaler in April this year. Lupin secured USFDAs approval for its Albuterol Sulfate Inhalation Aerosol in August 2020.

Powered by Capital Market - Live News

   Attention Investors : Prevent Unauthorized Transactions in your demat account --> Update your Mobile Number with your Depository Participant. Receive alerts on your Registered Mobile for all debit and other important transactions in your demat account directly from CDSL on the same day........issued in the interest of investors.
   Attention Investors : Prevent unauthorised transactions in your account Update your mobile numbers/email IDs with your stock brokers / Depository Participant. Receive information of your transactions directly from Exchange / Depositories on your mobile / email at the end of the day .... Issued in the interest of Investors.
   Attention Investors : KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
   Attention Investors : No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
Email ID: info@ssplwealth.com       Customers grievances : grievances@ssplwealth.com     Compliance officer : Mr.G Anand , anand@ssplwealth.com
Hit Count : 15094736
SEBI Regn.Nos : NSE/BSE-INZ000192638 | CDSL : IN-DP-262-2016  |  MCX : INZ000081736
Member IDs : NSE : 11221 | BSE : 6292 | CDSL : 12045000 | MCX : 12815 | AMFI Regn.No : 2662
Designed , Developed & Content provided by CMOTS INFOTECH.(ISO 9001:2015 certified) © Copyright 2011 All Rights Reserved. Saravana Stocks Pvt. Ltd